Releasing Access to Medicines Summit Catalogue | Takeda Philippines
Takeda Healthcare Philippines releases Access to Medicines Summit Catalogue, identifies key areas to improve access to healthcare
Biopharmaceutical leader Takeda Healthcare Philippines Inc. (“Takeda Philippines”), together with its partners, recently released a Catalogue of Partnership Opportunities as part of its commitment to support the government in strengthening the Philippine healthcare system. Developed with insights and expertise gathered from their Access to Medicines summit held last October 11-12, 2022, in Manila, Philippines, the catalogue aims to provide various stakeholders ideas on possible collaborations between public and private entities, and opportunities to improve access to medicines for Filipinos.
The Access to Medicines Summit 2022 themed "Onward to a Transformed Healthcare System by 2030," brought together a diverse range of stakeholders guided by the vision for a sustained access to quality and affordable medicines and vaccines and reduced out-of-pocket health spending aligned with the Sustainable Development Goals (SDGs), specifically SDG 3.8 and the Universal Healthcare (UHC) Act.
Based on data from state-owned Philippine Health Insurance Corporation (PhilHealth) in 2022, Filipinos still shoulder out-of-pocket expenditure ranging from 34 to 44.7 percent1. The elderly, women, rural and poor Filipinos are more likely to spend more.
"The Catalogue of Partnership Opportunities is an invaluable resource for stakeholders from different sectors, advocating for collaboration and innovation,” Loreann Villanueva, Country Manager of Takeda Healthcare Philippines shared. “At Takeda Healthcare Philippines, we believe in the power of partnerships to improve access to medicines and enhance the overall health and well-being of Filipinos. Ensuring that quality healthcare services reach every individual in the country requires collective efforts from the public and private sectors. In the area of cancer management, for example, we have made efforts to implement unique patient assistance programs that consider the patient’s capacity to pay, in collaboration with their healthcare providers. This allows us to provide Filipino patients with broader access to innovative therapies for blood cancers such as lymphoma and multiple myeloma."
The Catalogue of Partnership Opportunities encapsulates the combined aspirations, success stories and insights shared by the attendees of the summit. It serves as a comprehensive resource that captures the ideas of stakeholders who were physically present at the event, as well as those whose perspectives were represented by their organizations.
“The health of our country is not just about being free of certain illnesses alone, but it’s about total health services and wellness, and improved quality of life,” Secretary Benjamin Abalos Jr. of the Department of Interior and Local Government shared. Abalos highlighted the importance of working with the Local Government Units to improve access to medicines and achieve universal healthcare in the country.
“This partnership helps to identify major and critical barriers to medicine access,” Val Ulep, Senior Research Fellow of the Philippine Institute for Development Studies (PIDS) said. “Through this collaboration, we are also able to come up with innovative ways on how to overcome these setbacks.”
The catalogue identified eight key areas for partnership opportunities: access programs, capacity building, data management, digitalization, health information management and communication, policy and governance, supply chain management, and sustainable health financing.
“The goal is to make the catalogue accessible to all and raise awareness about the multitude of partnership opportunities available to drive the transformation of the Philippine healthcare system by 2030. We believe that the best way to ensure patients have timely access to medicines is by building trusted, effective and lasting local partnerships. By strengthening health systems together, we can better support the patient journey through health promotion and prevention, diagnosis, treatment and ongoing care,” added Villanueva.
While current health-related interventions and programs are in place, the catalogue highlights the untapped potential for collaboration that can further enhance access to medicines and other health technologies. Anchored by Takeda’s patient-first approach with their partners collectively, they aspire to combine resources, expertise, responsibilities, leadership, and coordination to address access barriers and strengthen local standards of care.
The Access to Medicines Summit 2022 participants includes representatives from the Department of Health, Department of Trade, and Industry, Department of the Interior and Local Government, healthcare professional societies, patient organizations, academia, financing institutions, NGOs and more. The summit is also in collaboration with RiseAboveNow Business Consulting as co-convenor and technical partner.
Read the Access to Medicines White Paper to learn more about the multi-stakeholder partnership and how it aims to improve medicine access in the Philippines.
About Takeda
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
About Takeda Philippines
Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.
For more information, visit https://www.takeda.com.
Media Contacts:
Takeda Philippines
Arabella Benedito - [email protected]
COMCO Southeast Asia
Ferdinand Bondoy - [email protected]
Joyce Yu - [email protected]
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,
“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Medical information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.